Pfizer Recalls Nearly 16,000 Bottles of Levoxyl Over Thyroid Drug Potency Concerns
Pfizer recalls nearly 16,000 bottles of Levoxyl thyroid medication after potency testing concerns. Learn about affected lot numbers, FDA classification, and patient safety guidance.
Pfizer Issues Recall for Thousands of Levoxyl Bottles
Pfizer has voluntarily recalled nearly 16,000 bottles of Levoxyl, a prescription medication commonly used to treat an underactive thyroid, after testing revealed that certain tablets did not meet required potency specifications.
According to published federal recall information, the action affects specific lots of Levoxyl containing 175 micrograms of levothyroxine sodium, the active ingredient responsible for replacing the thyroid hormone that the body cannot produce in sufficient quantities.
The recall has raised concerns about medication quality and the importance of ensuring that patients receive the prescribed amount of thyroid hormone. However, the action applies only to identified product lots, not every bottle of Levoxyl currently available.
Patients who take this medication are encouraged to review their prescription packaging and contact a pharmacist or health care professional if they believe their medication may be affected.
Which Levoxyl Products Are Included in the Recall?
The recall covers two packaging configurations of Levoxyl, according to the reported federal records.
The affected products include:
- 15,815 bottles containing 100 tablets each
- 134 bottles containing 1,000 tablets each
Both products contain levothyroxine sodium at a strength of 175 micrograms per tablet. The affected bottles have an expiration date of November 30, 2026.
The specific lot numbers identified in the recall are 24W06 and 24W07.
Patients should compare these details with the information printed on their medication bottles. The lot number is particularly important because the recall does not automatically apply to other strengths, packaging configurations, or production lots.
If the product details match those listed in the recall, patients should contact their dispensing pharmacy or prescribing clinician for guidance on confirming the recall status and obtaining an appropriate replacement.
Why Did Pfizer Recall the Thyroid Medication?
The stated reason for the recall was a confirmed out-of-specification assay result during stability testing.
In pharmaceutical manufacturing, an assay test measures the amount of active ingredient present in a medication. Stability testing helps determine whether a product continues to meet its quality requirements throughout its intended shelf life.
In this case, the reported test result indicated that the affected tablets did not meet the required potency specifications. This raises the possibility that the medication may contain less active ingredient than intended.
For patients taking thyroid replacement therapy, receiving the correct dose is important for maintaining hormone levels within the target range established by their health care provider.
The recall was initiated voluntarily by Pfizer on September 29, 2026. The U.S. Food and Drug Administration (FDA) classified it as a Class II recall on October 16, with relevant notices published on October 19, according to the supplied report.
A voluntary recall is a corrective action that a company can initiate to remove or address a product that does not meet applicable requirements. The FDA may oversee, classify, and communicate information about the recall.
What Is Levoxyl and Why Is It Prescribed?
Levoxyl is a prescription medication containing levothyroxine sodium, a synthetic form of thyroxine, also known as T4.
The thyroid gland normally produces hormones that help regulate metabolism, energy use, body temperature, and several other essential bodily functions.
When the thyroid gland does not produce enough hormone, a condition known as hypothyroidism can develop. Symptoms may include fatigue, sensitivity to cold, constipation, dry skin, and changes in body weight, although symptoms vary from person to person.
Levothyroxine helps replace the hormone that the body lacks. The medication is generally taken regularly, with the dosage adjusted according to individual medical needs and laboratory results.
Because thyroid hormone requirements can vary, maintaining consistent treatment is important. A product that delivers less active ingredient than expected could potentially affect the amount of hormone a patient receives.
What Does an FDA Class II Recall Mean?
The FDA uses recall classifications to communicate the potential health risks associated with defective or noncompliant products.
A Class II recall generally means that using or being exposed to the affected product may cause temporary or medically reversible adverse health consequences. The possibility of serious harm is considered remote.
This classification does not mean that every person who took the recalled medication will experience health problems. It also does not establish that a particular patient has suffered an injury.
The potential effect of a potency issue depends on several factors, including the extent of the deviation from specifications, how long the medication was used, and the patient's individual health circumstances.
For people taking levothyroxine, an insufficient dose may affect thyroid hormone control. However, the actual clinical impact cannot be determined from the recall classification alone.
Patients should consult a qualified health care professional rather than attempting to assess the potency or safety of their medication themselves.
What Should Patients Taking Levoxyl Do?
Patients who currently take Levoxyl can take several practical steps to determine whether their medication is affected.
1. Check the product information. Review the medication bottle for the product strength, lot number, and expiration date. The reported affected lots are 24W06 and 24W07, with an expiration date of November 30, 2026.
2. Contact a pharmacist. If the details match, contact the pharmacy that dispensed the medication to confirm whether the bottle is included in the recall and ask about replacement arrangements.
3. Speak with your prescribing clinician. Your health care provider can advise you on how to maintain appropriate thyroid treatment while addressing the recalled product.
4. Do not change treatment independently. Do not stop taking thyroid medication, alter your dosage, or substitute another product without appropriate professional guidance. Interrupting prescribed thyroid treatment may create additional health concerns.
5. Report any concerns. If you experience new or worsening symptoms, contact your health care professional. Seek urgent medical attention for severe or rapidly worsening symptoms.
The correct course of action may differ depending on your prescription, medical history, and whether your medication is confirmed to be part of the affected lots.
Other Thyroid Medication Recalls Reported in 2026
The Levoxyl recall follows other reported recalls involving thyroid medications in 2026.
According to the supplied report, certain lots of generic levothyroxine distributed by Major Pharmaceuticals were recalled in July because of potency concerns. Another recall announced in August involved a lot of thyroid tablets from Vitruvias Therapeutics because of potential excessive potency.
These reports highlight why pharmaceutical quality testing and product traceability are important. Medication potency can affect treatment in different ways depending on whether the active ingredient is present in an amount below or above the required specifications.
However, the circumstances and affected products differ between recalls. Patients should rely on the specific product details and official notices relevant to their medication rather than assuming that all thyroid treatments are affected.
Conclusion
Pfizer's recall of nearly 16,000 bottles of Levoxyl underscores the importance of medication quality and accurate dosing for people managing hypothyroidism.
The reported recall affects lots 24W06 and 24W07 of the 175-microgram formulation, with an expiration date of November 30, 2026. The FDA classified the action as Class II, indicating that the potential health consequences are generally temporary or medically reversible, with serious harm considered unlikely.
Patients should check their medication packaging, confirm any suspected match with a pharmacist, and consult their prescribing clinician about appropriate next steps. They should not independently stop or change their prescribed thyroid treatment.
Checking official recall notices and seeking professional advice can help patients respond appropriately while maintaining continuity of care.
Sources
- NTD Television, published October 19, 2026.
- U.S. Food and Drug Administration (FDA), drug recall classifications and guidance on pharmaceutical recalls.
- U.S. Food and Drug Administration (FDA), Drugs@FDA database for prescription drug information.
Disclaimer
This article is intended for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Recall details should be verified against the latest official FDA notices and manufacturer communications. Patients should consult their pharmacist or health care provider about potentially affected medication and should not stop, change, or replace prescribed treatment without professional guidance.